Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.
Also called NCT07374328
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 240 participants
- Registry
-
NCT07374328
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07374328. Randomized; single masking; primary purpose treatment. Start 2025-06-01 (actual); primary completion 2026-05-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus
- Acronym
- TRED
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Semaglutide (1 Mg Dose)
- Intervention (Drug)
- Sitagliptin (DPP4 inhibitor)
- Lead sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Record details
- Record id
cardio:ct-nct07374328- Content hash
e504bba4855f21d992e85aa101c879f994ab77e85449187064d0eb115d4c6c02